Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. / Jessen, Søren; Becker, Victoria; Rzeppa, Sebastian; Backer, Vibeke; Bengtsen, Kasper Høtoft; Hullstein, Ingunn; Dehnes, Yvette; Hostrup, Morten.
I: Drug Testing and Analysis, Bind 13, Nr. 4, 2021, s. 747-761.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control
AU - Jessen, Søren
AU - Becker, Victoria
AU - Rzeppa, Sebastian
AU - Backer, Vibeke
AU - Bengtsen, Kasper Høtoft
AU - Hullstein, Ingunn
AU - Dehnes, Yvette
AU - Hostrup, Morten
N1 - This article is protected by copyright. All rights reserved.
PY - 2021
Y1 - 2021
N2 - As of 2020, use of beta2-agonist salmeterol is restricted by the World Anti-Doping Agency (WADA) and is only permitted by inhalation at therapeutic doses not exceeding 200 μg in 24 h. In contrast to beta2-agonists salbutamol and formoterol, WADA has not established a urine threshold for salmeterol despite its muscle hypertrophic actions observed in animals. Herein, we investigated plasma (0-4 h) and urine (0-24 h) concentrations (by UHPLC-MS/MS) of salmeterol and α-hydroxysalmeterol after dry powder inhalation at supratherapeutic (400 μg) and high therapeutic (200 μg) doses, and after 7 consecutive days of therapeutic inhalation (200 μg×day-1) in 11 healthy endurance-trained men. During each trial, participants inhaled salmeterol before 1½ h moderate-intensity cycling. Mean±SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0±1.6, 2.1±1.5, and 2.2±1.1 ng×mL-1 for 400 μg, 200 μg, and 7 consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6±6.1, 5.7±4.6, and 6.5±2.6 ng×mL-1. Within the relevant window for doping control (first 6 h post-inhalation), the present data (119 samples), along with 64 biobank urine samples, showed that a combined salmeterol and α-hydroxysalmeterol urine threshold with equal cut-offs of 3.3 ng×mL-1 was superior to a salmeterol-only threshold to discriminate therapeutic (200 μg) from supratherapeutic use (400 μg) with a sensitivity of 24% with 0% false positives when applying the WADA technical document (TD2019DL.v2) method of specific gravity adjustment. Thus, a combination of urine salmeterol and α-hydroxysalmeterol concentrations may be suitable for discriminating between therapeutic and supratherapeutic prohibited inhalation of salmeterol.
AB - As of 2020, use of beta2-agonist salmeterol is restricted by the World Anti-Doping Agency (WADA) and is only permitted by inhalation at therapeutic doses not exceeding 200 μg in 24 h. In contrast to beta2-agonists salbutamol and formoterol, WADA has not established a urine threshold for salmeterol despite its muscle hypertrophic actions observed in animals. Herein, we investigated plasma (0-4 h) and urine (0-24 h) concentrations (by UHPLC-MS/MS) of salmeterol and α-hydroxysalmeterol after dry powder inhalation at supratherapeutic (400 μg) and high therapeutic (200 μg) doses, and after 7 consecutive days of therapeutic inhalation (200 μg×day-1) in 11 healthy endurance-trained men. During each trial, participants inhaled salmeterol before 1½ h moderate-intensity cycling. Mean±SD maximum urine concentrations of salmeterol unadjusted for specific gravity reached 4.0±1.6, 2.1±1.5, and 2.2±1.1 ng×mL-1 for 400 μg, 200 μg, and 7 consecutive days of 200 μg, respectively, with corresponding maximum urine concentrations of α-hydroxysalmeterol being 11.6±6.1, 5.7±4.6, and 6.5±2.6 ng×mL-1. Within the relevant window for doping control (first 6 h post-inhalation), the present data (119 samples), along with 64 biobank urine samples, showed that a combined salmeterol and α-hydroxysalmeterol urine threshold with equal cut-offs of 3.3 ng×mL-1 was superior to a salmeterol-only threshold to discriminate therapeutic (200 μg) from supratherapeutic use (400 μg) with a sensitivity of 24% with 0% false positives when applying the WADA technical document (TD2019DL.v2) method of specific gravity adjustment. Thus, a combination of urine salmeterol and α-hydroxysalmeterol concentrations may be suitable for discriminating between therapeutic and supratherapeutic prohibited inhalation of salmeterol.
KW - Faculty of Science
KW - Anti-doping
KW - Beta2-adrenoceptor agonists
KW - Beta-agonist
KW - LABA
KW - Pharmacology
U2 - 10.1002/dta.2978
DO - 10.1002/dta.2978
M3 - Journal article
C2 - 33210444
VL - 13
SP - 747
EP - 761
JO - Drug Testing and Analysis
JF - Drug Testing and Analysis
SN - 1942-7603
IS - 4
ER -
ID: 251791648